LONDON–(BUSINESS WIRE)–EMMAC Life Sciences Ltd, the European independent medical cannabis company, is pleased to announce that Medalchemy, EMMAC’s fully-licensed GMP certified laboratory in Alicante, Spain, has secured approval from the Spanish Health Authorities AEMPS to import medical cannabis for scientific research. This landmark announcement places Medalchemy at the forefront of medical cannabis research in Spain, and ensures EMMAC is well positioned to capitalise on anticipated regulatory changes, as demand for premium quality medical cannabis grows in Spain and across Europe.
With over a decade of experience in the research, development and
manufacture of active pharmaceutical ingredients (APIs), Medalchemy is
an important part of EMMAC’s pan-European research and development
initiative to allow the production, registration and exportation of
GMP-certified cannabinoid-based APIs.
Antonio Costanzo, CEO of EMMAC, commented: “This is an
important milestone for EMMAC, as the Company executes on its strategy
to bring specific cannabis regulatory expertise to its expanding asset
base, and create a vertically integrated multi-national operation that
positions EMMAC at as a trusted leader in the rapidly-growing medical
cannabis industry in Europe.”